Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles British Journal of Clinical Pharmacology Year : 2008

Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Abstract

Highly active antiretroviral therapy is recommended for HIV-infected pregnant women to prevent mother-to-child transmission. The specific physiological background induced by pregnancy leads to significant changes in maternal pharmacokinetics, suggesting potential variability in plasma concentrations of antiretrovirals during gestation. Therapeutic drug monitoring (TDM) of protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) is recommended in certain situations, including pregnancy, but its systematic use in HIV-infected pregnant women remains controversial. This review provides an update of the pharmacokinetic data available for PIs and NNRTIs in pregnant women and highlights the clinical interest of systematic TDM of certain antiretroviral drugs during pregnancy, including nevirapine, nelfinavir, saquinavir, indinavir and lopinavir.
Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-00361996 , version 1 (17-02-2009)

Identifiers

Cite

Matthieu Roustit, Malik Jlaiel, Pascale Leclercq, Françoise Stanke-Labesque. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.. British Journal of Clinical Pharmacology, 2008, 66 (2), pp.179-95. ⟨10.1111/j.1365-2125.2008.03220.x⟩. ⟨inserm-00361996⟩

Collections

INSERM UGA
39 View
2 Download

Altmetric

Share

Gmail Facebook X LinkedIn More